Skip to main content

Solvay to take impairment

In a Q2 trading update, Solvay revealed that an impairment review is under way and likely to lead to a non-cash impairment of about €1.5 billion. This is the result of “the deterioration in short and mid term economic performance due to Covid-19,” the company said.

Subscribe to impairment

 

 

 

AMRI banner advert